These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17175202)

  • 21. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.
    Mauermann ML; Blumenreich MS; Dispenzieri A; Staff NP
    Muscle Nerve; 2012 Dec; 46(6):970-7. PubMed ID: 23225391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 23. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
    Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
    Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
    Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
    Rosiñol L; Montoto S; Cibeira MT; Bladé J
    Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 28. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
    Jagannath S; Durie BG; Wolf JL; Camacho ES; Irwin D; Lutzky J; McKinley M; Potts P; Gabayan AE; Mazumder A; Crowley J; Vescio R
    Br J Haematol; 2009 Sep; 146(6):619-26. PubMed ID: 19622094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
    Manochakian R; Miller KC; Chanan-Khan AA
    Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variation associated with bortezomib-induced peripheral neuropathy.
    Favis R; Sun Y; van de Velde H; Broderick E; Levey L; Meyers M; Mulligan G; Harousseau JL; Richardson PG; Ricci DS
    Pharmacogenet Genomics; 2011 Mar; 21(3):121-9. PubMed ID: 21228734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 36. Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
    Mangiacavalli S; Corso A; De Amici M; Varettoni M; Alfonsi E; Lozza A; Lazzarino M
    Br J Haematol; 2010 Jun; 149(6):916-8. PubMed ID: 20201942
    [No Abstract]   [Full Text] [Related]  

  • 37. Expanding role of bortezomib in multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J
    Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib (velcade) for multiple myeloma.
    Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
    Meregalli C; Canta A; Carozzi VA; Chiorazzi A; Oggioni N; Gilardini A; Ceresa C; Avezza F; Crippa L; Marmiroli P; Cavaletti G
    Eur J Pain; 2010 Apr; 14(4):343-50. PubMed ID: 19695912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.